Past, present and future of erythropoietin use in the elderly

被引：0

作者：

De Francisco A.L.M. ^{[1
]}

Fernandez Fresnedo G. ^{[1
]}

Rodrigo E. ^{[1
]}

Piñera C. ^{[1
]}

Heras M. ^{[1
]}

Palomar R. ^{[1
]}

Ruiz J.C. ^{[1
]}

Arias M. ^{[1
]}

机构：

[1] Nephrology Service, Hospital Universitario Marqúes de Valdecilla, 39008 Santander, Avda Valdecilla s/n

来源：

International Urology and Nephrology | 2002年 / 33卷 / 1期

关键词：

Public Health; Iron; Renal Failure; Anemia; Folate;

D O I：

10.1023/A:1014478704766

中图分类号：

学科分类号：

摘要：

More than a decade has passed since the first patient with end-stage renal failure was treated with erythropoietin (EPO) and more than 85% of patients now receive this therapy. In the year 2002 more than 60% of dialysis patients will be elderly, and the treatment of anemia will be more complex due to the additional causes: folate, iron and vitamin deficiency in this population. Correction of anemia with EPO brings about partial regression of left ventricular hypertrophy and some data suggest that such treatment reduces cardiovascular mortality in patients without advance cardiac disease. Normalization of hematocrit with EPO increases oxygen supply to the brain tissue with improvement in brain function. The improvement in the ability to recognize, discriminate and hold stimuli in memory for difficult tasks is particularly important for elderly people. No differences have been noted in the incidence of clotting of vascular access in patients treated with EPO compared with hemodialysis patients not so treated. Also no one has demonstrated that treatment with EPO accelerates renal decline in patients with progressive renal insufficiency. In elderly people with anemia secondary to advanced renal failure, EPO therapy improves physical, cognitive and sexual function, and health related quality of life.

引用

页码：187 / 193

页数：6

共 47 条

[1]

Cameron J.S., Towards the millenium: A history of renal anaemia and the optimal use of epoetin, Nephrol Dial Transplant, 14, S2, pp. 10-21, (1999)

[2]

Winearls C.G., Historical review on the use of recombinant human erythropoietin in chronic renal failure, Nephrol Dial Transplant, 10, S2, pp. 3-9, (1995)

[3]

European Survey on Anaemia Management Update, (1999)

[4]

Eschbach J.W., The future of r-HuEPO, Nephrol Dial Transplant, 10, S2, pp. 96-109, (1995)

[5]

Levin A., Singer J., Thomson C.R., Ross H., Lewis M., Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention, Am J Kidney Dis, 27, pp. 347-354, (1996)

[6]

Revicki D.A., Brown R.E., Feeny D.H., Et al., Health related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients, Am J Kidney Dis, 25, pp. 548-554, (1995)

[7]

Levin A., How should anaemia be managed in predialysis patients, Nephrol Dial Transplant, 14, S2, pp. 66-74, (1999)

[8]

Roth D., Smith R.D., Schulman G., Et al., Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients, Am J Kidney Dis, 24, (1994)

[9]

Silberberg J.S., Barre P.E., Prichard S.S., Sniderman S.D., Impact of left ventricular hypertrophy on end stage renal disease, Kidney Int, 36, pp. 286-290, (1989)

[10]

London G.M., Zins B., Pannier B., Et al., Vascular changes in hemodialysis patients in response to recombinant human erythropoietin, Kidney Int, 36, pp. 878-882, (1989)

← 1 2 3 4 5 →